- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00833794
A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis
25. April 2012 aktualisiert von: Labopharm Inc.
The purpose of this study is to compare the analgesic efficacy, safety and clinical benefit of Tramadol OAD tablets versus Placebo.
Studienübersicht
Status
Abgeschlossen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
1028
Phase
- Phase 3
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
40 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria for Open-Label phase:
- Males or females
- Must be between the ages of 40-80
Must meet the American College of Rheumatology (ACR) Clinical Classification Criteria for Osteoarthritis of the Knee:
- Current knee pain
- Less than 30 minutes of morning stiffness with or without crepitus on active motion
- Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within five years prior to entry into the study
- Must have a history of exposure to treatment (for pain due to osteoarthritis (OA) of the knee) with Non-steroidal anti-inflammatory drugs (NSAIDs), COX II inhibitors or tramadol.
- Must be taking one of the above medications on a regular basis in the 30 days prior to Visit 2 (S0).
Must meet the following criteria for severity of pain at Visit 2 (Day S0):
- Have a score of ≥ 4 on the 11-point Numerical Rating Scale (PI-NRS; range: 0-10)
- Have a total increase of ≥ 2 points on the 11-point Numerical Rating Scale (range: 0-10) compared to the rating at Visit 1 (Day SX)
- Must have a erythrocyte sedimentation rate (ESR) < 40 mm/hr
- Must have oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials
- Must have signed and dated an approved written Informed Consent form in French, Spanish, English or Romanian, which has also been signed and dated by the Investigator (unless otherwise required by the ethics committee), prior to study participation
Exclusion Criteria for Open-Label phase:
- Has known rheumatoid arthritis or any other rheumatic disease
- Has secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; target joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations
- Has a history of bursitis of the knee (target knee)
- Has a history of pain in the ipsilateral hip (target knee)
- Has had a meniscal tear in the target knee within the last 12 months
- Has had cartilage reconstruction procedure in the target knee
- Has had a therapeutic arthroscopy procedure in the target knee within the last 12 months
- Has a Body Mass Index (BMI) greater than 37
- Has had a major illness, requiring hospitalisation during the 3 months before commencement of the screening period
- Is unwilling to stop taking pain medication other than the study medication (for arthritis or other types of pain) or is unwilling to stop taking other medications for the treatment of OA
- Has previously failed treatment with tramadol or discontinued treatment with tramadol due to adverse events
- Has been taking other opioids (e.g. codeine, oxycodone, hydromorphone, etc.) for treatment of OA or other chronic conditions
- Has received Corticosteroid Injections in the target knee within the last 3 months or Viscous injections in the target knee within the last 6 months
- Has had treatment within the last 3 weeks with any of the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; serotonin-norepinephrine reuptake inhibitors or any other drug that reduces seizure threshold
- Has had treatment with another investigational agent within the last 30 days
- Has a history of seizure disorder other than Infantile Febrile Seizures
- Has a previous or current opioid dependency
- Has a bowel disease causing malabsorption
- Is pregnant, lactating or of childbearing potential and is unwilling to utilise a medically approved method of contraception during participation in this clinical trial
- Has significant liver disease, defined as active hepatitis or elevated liver enzymes >3 times the upper boundary of the normal range
- Has significant renal disease (defined as creatinine clearance <30 mL/min
- Has a history of current or past substance abuse or dependence, other than nicotine
- Has a known and documented allergy to tramadol or any structurally similar drugs (e.g. opiates)
- Has a known and documented allergy to acetaminophen or any structurally similar drugs
- Has any other condition that, in the opinion of the Investigators, would adversely affect the patient's ability to complete the study or its measures.
Inclusion criteria for the double-blinded phase:
- Patients must continue to meet the open-label eligibility criteria and
- Must have a score of ≥ 4 on the Numerical Rating Scale (NRS) with a total increase of ≥ 2 points on the NRS compared to Visit 3(Day R14) and
- Must not have taken any of the prohibited medications during the Open-label Phase.
Exclusion criteria for the double-blinded phase:
- Patient Request
- Adverse Events that contraindicate further administration of the study medication
- Any other situation where in the opinion of the Investigator continued participation in the study would not be in the patient's best interest.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: 2 Placebo
|
|
Experimental: 1 Tramadol Once A Day
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pain Intensity Score as Measured by the 11-point Pain Intensity-Numerical Rating Scale Score at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: 12 weeks
|
The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain.
The mean score at the end of the study (week 12 or time of discontinuation) was calculated.
|
12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pain Intensity Score (11-point PINRS) After 6 Weeks of Maintenance Treatment
Zeitfenster: 6 weeks
|
The Pain Intensity Score is an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain
|
6 weeks
|
Pain Intensity Score Stratified by Dose, at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: 12 weeks
|
Pain Intensity Score (an 11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) was stratified by final dose level, at week 12 or time of discontinuation.
The final optimum dose level based upon efficacy and tolerability was kept for the entire study.
The mean score was calculated.
|
12 weeks
|
WOMAC Pain Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: 12 weeks
|
Mean WOMAC Pain Subscale score at week 12.
The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme).
The WOMAC pain subscale results from the sum of 5 pain questions.
The maximum total score is 20.
|
12 weeks
|
WOMAC Physical Function Subscale Score at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: 12 weeks
|
Mean WOMAC Physical Function Subscale score at week 12.
The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 5-point Likert-scale ranging from no difficulty to extreme difficulty (0-none; 1-slight; 2-moderate; 3-severe; 4-extreme).
The WOMAC Physical Function subscale results from the sum of 17 physical function questions and the maximum possible score is 68.
|
12 weeks
|
Patient Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: 12 weeks
|
This assessment of overall status integrates the effect of the treatment on pain, side effects, and the patient's expectation of pain relief.
It is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)
|
12 weeks
|
Physician Global Impression of Change at the End of the Study (Week 12 or Time of Discontinuation)
Zeitfenster: week 12
|
This assessment of overall impression of study drug is made using a 7-point categorical scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse)
|
week 12
|
Time to Response
Zeitfenster: 12 weeks
|
Response was defined as a decrease of ≥1 point in an 11-point PINRS (11-point pain intensity numerical rating scale ranging from 0: no pain to 10: worst possible pain) from baseline to the last visit.
The time to response was estimated using Kaplan-Meier analysis and a 95% CI for the median time was calculated.
|
12 weeks
|
Discontinuation Due to Lack of Efficacy
Zeitfenster: 12 weeks
|
The number of patients who discontinued due to lack of efficacy was reported.
|
12 weeks
|
Discontinuation Due to Adverse Events
Zeitfenster: 12 weeks
|
The number of patients who discontinued due to adverse events (AEs).
An AE is defined as any untoward medical event that occurs during the course of a clinical investigation in which a patient is administered a pharmaceutical or other therapeutic product.
Its occurrence does not necessarily imply a causal relationship with the treatment.
|
12 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Nützliche Links
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2004
Primärer Abschluss (Tatsächlich)
1. Januar 2006
Studienabschluss (Tatsächlich)
1. Januar 2006
Studienanmeldedaten
Zuerst eingereicht
29. Januar 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
30. Januar 2009
Zuerst gepostet (Schätzen)
2. Februar 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
30. April 2012
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
25. April 2012
Zuletzt verifiziert
1. April 2012
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Gelenkerkrankungen
- Erkrankungen des Bewegungsapparates
- Rheumatische Erkrankungen
- Arthritis
- Arthrose
- Physiologische Wirkungen von Arzneimitteln
- Depressiva des zentralen Nervensystems
- Agenten des peripheren Nervensystems
- Analgetika
- Agenten des sensorischen Systems
- Analgetika, Opioide
- Betäubungsmittel
- Tramadol
Andere Studien-ID-Nummern
- MDT3-005
- NCT00833794 (Registrierungskennung: ClinicalTrials.gov)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schmerzen
-
Foundation IRCCS San Matteo HospitalAktiv, nicht rekrutierendGreater Trochanteric Pain Syndrome beider unteren ExtremitätenItalien
-
Gazi UniversityAbgeschlossenGesäß-Tendinitis | Greater Trochanteric Pain Syndrome beider unteren ExtremitätenTruthahn
-
Lawson Health Research InstituteNoch keine RekrutierungSchmerzen im unteren Rücken | Greater Trochanteric Pain Syndrome
-
C.R.Darnall Army Medical CenterUnbekanntGreater Trochanteric Pain SyndromeVereinigte Staaten
-
Guna S.p.aBeendetGreater Trochanteric Pain Syndrome | Pertrochantäre Fraktur | Gesäß-Tendinitis | GTPS - Greater Trochanteric Pain Syndrome | Sehnenerkrankung | GesäßmuskulaturItalien
-
Smith & Nephew, Inc.AbgeschlossenHüftschmerzen chronisch | Greater Trochanteric Pain SyndromeAustralien
-
NHS Greater Glasgow and ClydeNHS Research ScotlandRekrutierungGreater Trochanteric Pain SyndromeVereinigtes Königreich
-
Kutahya Health Sciences UniversityRekrutierungGreater Trochanteric Pain SyndromeTruthahn
-
Massachusetts General HospitalAbgeschlossenGreater Trochanteric Pain SyndromeVereinigte Staaten
-
Montefiore Medical CenterNoch keine RekrutierungGreater Trochanteric Pain SyndromeVereinigte Staaten
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich